503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Zero-Dependency Pharmacoeconomic Tool · Powered by DOI 10.5281/zenodo.24139325

GLP-1 Insurance Deductible & Prior-Authorization vs. $49 Cash-Pay Calculator (2026)

Compare your remaining commercial health plan deductible, monthly copay, and PA step-therapy wait time against immediate $49/mo Semaglutide or $99/mo Tirzepatide cash care.

Est. 12-Month Insurance OOP
$3,075
12-Month Direct Flat Rate
$588
Net Cash-Bypass Savings
$2,487

Underlying Empirical Dataset Citation

All default provider rates, PBM thresholds, and bioavailability coefficients in this tool are drawn directly from our open-access CC-BY-4.0 dataset (us-commercial-insurance-glp1-pa-denial-formulary-2026 · Academic DOI 10.5281/zenodo.24139325).

Ready to Lock In Your Verified Flat Rate?

$0 platform membership, $0 high-dose escalation surcharges, and free express cold-chain shipping.

Skip PBM Denials — Start at $49/mo →

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in GLP-1 Insurance Deductible & Prior-Authorization vs. $49 Cash-Pay Calculator (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Capehorn, M., Johansson, E., Davies, A., Evans, J., Godbeer, F., van Hest, N., Cotterill, G., & Tolley, K. (2025). Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. Advances in therapy, 42(10), 5055-5071. https://doi.org/10.1007/s12325-025-03288-3
  2. Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025). Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA health forum, 6(3), e245586. https://doi.org/10.1001/jamahealthforum.2024.5586
  3. Mattingly TJ 2nd, & Conti, R. M. (2025). Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists. JAMA health forum, 6(1), e245015. https://doi.org/10.1001/jamahealthforum.2024.5015
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know